Dual Antiplatelet Therapy in Patients With Minor Stroke Receiving Intravenous Thrombolysis

Zhaohan Xu, Nihong Chen, Huiling Sun, Teng Jiang, Qiwen Deng, Junshan Zhou, Yingdong ZhangFrontiers in Neurology 2022 · DOI

Abstract

Dual antiplatelet therapy (DAPT) may be a potential therapeutic approach in patients with minor stroke receiving intravenous thrombolysis (IVT). This study investigates the safety and efficacy of DAPT compared to single antiplatelet therapy (SAPT) in this specific patient population. Further randomized controlled trials are required to confirm this finding.

Introduction

When a patient suffers an ischemic stroke, the standard "clot-busting" treatment is Intravenous Thrombolysis (IVT). For "minor" strokes—defined as a score of 3 or less on the National Institutes of Health Stroke Scale (NIHSS)—clinical guidelines recommend Dual Antiplatelet Therapy (DAPT) to prevent recurrence. However, combining IVT and DAPT raises concerns about a "double-thinning" effect, potentially leading to symptomatic intracerebral hemorrhage (sICH). This study provides real-world evidence on the safety and efficacy of this combination.

Methods

This retrospective study analyzed data from 855 consecutive patients at the National Advanced Stroke Center of Nanjing First Hospital, China, between 2016 and 2021.

Figure 1: Flowchart of patient recruitment and group allocation.

The researchers focused on 245 eligible patients with minor strokes (NIHSS ≤ 3) who received IVT. Of these, 118 received Single Antiplatelet Therapy (SAPT; aspirin or clopidogrel), and 127 received DAPT (both drugs) for at least 21 days, starting 24 hours after IVT. To ensure a fair comparison, Propensity Score Matching (PSM) was used to match patients based on baseline characteristics.

Results

The study found that DAPT was significantly more effective than SAPT for functional recovery without increasing safety risks.

Table 2: Comparison of primary and secondary outcomes between SAPT and DAPT groups.

Key Findings:

  • Superior Recovery: Patients on DAPT were significantly more likely to achieve an excellent functional outcome (mRS 0–1) at 90 days (88.98% vs 78.81%, $p = 0.030$). The adjusted odds ratio (OR) for an excellent outcome was 2.76 (95% CI 1.27–6.01, $p = 0.010$), meaning DAPT patients had nearly triple the odds of a full recovery.
  • Safety Profile: The feared increase in brain bleeds did not occur. The rate of sICH was actually lower in the DAPT group (0.79%) compared to the SAPT group (1.69%), though not statistically significant ($p = 0.610$).
  • Recurrence: No significant difference was found in recurrent stroke within 90 days (3.15% for DAPT vs. 3.39% for SAPT).

DAPT appeared particularly beneficial for patients with large-artery atherosclerosis, suggesting it may help stabilize plaques that IVT alone cannot fully resolve.

Conclusion

While DAPT shows promise as a safe and effective treatment for minor stroke patients following IVT, the authors emphasize that these findings from a retrospective, single-center study must be confirmed by large-scale randomized controlled trials (RCTs) before clinical guidelines are changed.

Summary updated

Abstract

Dual antiplatelet therapy may be a potential therapeutic approach in patients with minor stroke receiving IVT. Further randomized controlled trials are required to confirm this finding.
BibTeX
@inproceedings{xu2022dual,
  author = {Zhaohan Xu and Nihong Chen and Huiling Sun and Teng Jiang and Qiwen Deng and Junshan Zhou and Yingdong Zhang},
  title = {{Dual Antiplatelet Therapy in Patients With Minor Stroke Receiving Intravenous Thrombolysis}},
  booktitle = {Frontiers in Neurology},
  year = {2022},
  doi = {10.3389/fneur.2022.819896},
}
Figure